OCS Heart: Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.
Static Cold Storage (SCS): Preservation of donor hearts with static cold storage.
Study summary
This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):
Donor Inclusion Criteria
* Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
* All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \<50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.
* DBD donor hearts with an expected cross clamp of ≥ 4 hours
* DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:
* Donor age ≥ 40 years old
* Unknown downtime
* Insignificant CAD
* LVEF ≤ 50%
Donor Exclusion • Moderate to severe aortic incompetence
Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):
Donor Inclusion Criteria
* Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
* Eligible for randomization to OCS or SCS treatment arms.
* DBD donor hearts with an expected cross clamp time of \< 4 hours.
Donor Exclusion
* Moderate to severe aortic incompetence
* DBD donor with any of the following organ quality concerns:
* Donor age ≥ 40 years old
* Unknown downtime
* Insignificant CAD
* LVEF ≤ 50%
Recipient Eligibility Criteria (for Part A and B Cohorts)
Inclusion
* Signed informed consent document and authorization to use and disclose protected health information
* Heart transplant candidate
* Age ≥ 18 years old
Exclusion
• Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial
Primary outcome measure(s)
Patient and graft survival — 30-day post transplant The primary endpoint is 30-day patient and graft survival with freedom from moderate or severe LV or RV primary graft dysfunction (PGD) in the first 24 hours post-transplant.
Trial sites (8)
Facility
City
Region
Status
University of California San Francisco
San Francisco
California
Recruiting
Tampa General Hospital
Tampa
Florida
Recruiting
Massachusetts General Hospital
Boston
Massachusetts
Recruiting
Mount Sinai
New York
New York
Recruiting
Columbia University Irving Medical Center/ New York Presbyterian Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.